Dulera

Dulera is a brand name of formoterol/mometasone, approved by the FDA in the following formulation(s):

DULERA (formoterol fumarate; mometasone furoate - aerosol, metered; inhalation)

• 
  Manufacturer: SCHERING
  
  Approval date: June 22, 2010
  
  Strength(s): 0.005MG/INH;0.1MG/INH ^[RLD], 0.005MG/INH;0.2MG/INH ^[RLD]

Has a generic version of Dulera been approved?

No. There is currently no therapeutically equivalent version of Dulera available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Dulera. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Use of mometasone furoate for treating lower airway passage and lung diseases
  Patent 5,889,015
  Issued: March 30, 1999
  Inventor(s): Sequeira; Joel A. & Cuss; Francis M. & Nolop; Keith B. & Chaudry; Imtiaz A. & Nagabhushan; Nagamani & Patrick; James E. & Cayen; Mitchell
  Assignee(s): Schering Corporation
  The administration of aerosolize particles of mometasone furoate in the form of dry powders, solutions, or aqueous suspension for treating corticosteroid-responsive diseases of the surfaces of upper and/or lower airway passages and/or lungs, e.g., allergic rhinitis and asthma is disclosed.
  
  Patent expiration dates:
  
  
  • January 27, 2014
    
    ✓ 
    Patent use: TREATMENT OF ASTHMA
  
  
  
  • July 27, 2014
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Use of mometasone furoate for treating airway passage and lung diseases
  Patent 6,057,307
  Issued: May 2, 2000
  Inventor(s): Sequeira; Joel A. & Cuss; Francis M. & Nolop; Keith B. & Chaudry; Imtiaz A. & Nagabhushan; Nagamani & Patrick; James E. & Cayen; Mitchell
  Assignee(s): Schering Corporation
  The administration of aerosolize particles of mometasone furoate in the form of dry powders, solutions, or aqueous suspension for treating corticosteroid-responsive diseases of the surfaces of upper and/or lower airway passages and/or lungs, e.g., allergic rhinitis and asthma is disclosed.
  
  Patent expiration dates:
  
  
  • January 27, 2014
    
    ✓ 
    Patent use: TREATMENT OF ASTHMA
    ✓ 
    Drug product
  
  
  
  • July 27, 2014
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Chlorofluorocarbon-free mometasone furoate aerosol formulations
  Patent 6,068,832
  Issued: May 30, 2000
  Inventor(s): Berry; Julianne & Sequeira; Joel A. & Chaudry; Imtiaz A.
  Assignee(s): Schering Corporation
  The invention relates to suspension aerosol formulations which exhibit stable particle sizes, containing mometasone furoate, about 1 to about 10 weight percent ethanol and 1,1,1,2,3,3,3-Heptafluoropropane as the propellant. A surfactant, such as oleic acid, can also be included. These formulations are suitable for use in metered dose inhalers.
  
  Patent expiration dates:
  
  
  • August 27, 2017
    
    ✓ 
    Patent use: TREATMENT OF ASTHMA
    ✓ 
    Drug product
  
  



• 
  Use of mometasone furoate for treating airway passage and lung diseases
  Patent 6,677,323
  Issued: January 13, 2004
  Inventor(s): Joel A.; Sequeira & Francis M.; Cuss & Keith B.; Nolop & Imtiaz A.; Chaudry & Nagamani; Nagabhushan & James E.; Patrick & Mitchell; Cayen
  Assignee(s): Schering Corporation
  The administration of aerosolize particles of mometasone furoate in the form of dry powders, solutions, or aqueous suspension for treating corticosteroid-responsive diseases of the surfaces of upper and/or lower airway passages and/or lungs, e.g., allergic rhinitis and asthma is disclosed.
  
  Patent expiration dates:
  
  
  • January 27, 2014
    
    ✓ 
    Patent use: TREATMENT OF ASTHMA
  
  



• 
  Combinations of formoterol and mometasone furoate for asthma
  Patent 7,067,502
  Issued: June 27, 2006
  Inventor(s): Hassan; Ian Francis & Clarke; Jeremy Guy & Danahay; Henry Luke
  Assignee(s): Novartis AG
  A medicament containing, separately or together, (A) formoterol or a pharmaceutically acceptable salt thereof or a solvate of formoterol or a solvate of the salt and (B) mometasone furoate, for simultaneous, sequential or separate administration in the treatment of an inflammatory or obstructive airways disease.
  
  Patent expiration dates:
  
  
  • May 21, 2020
    
    ✓ 
    Patent use: TREATMENT OF ASTHMA
    ✓ 
    Drug product
  
  



• 
  Combination of formoterol and mometasone furoate for asthma
  Patent 7,566,705
  Issued: July 28, 2009
  Inventor(s): Hassan; Ian F & Clarke; Jeremy G & Danahay; Henry L
  Assignee(s): Novartis AG
  A medicament containing, separately or together, (A) formoterol or a pharmaceutically acceptable salt thereof or a solvate of formoterol or a solvate of the salt and (B) mometasone furoate, for simultaneous, sequential or separate administration in the treatment of an inflammatory or obstructive airways disease.
  
  Patent expiration dates:
  
  
  • May 8, 2020
    
    ✓ 
    Patent use: TREATMENT OF ASTHMA
    ✓ 
    Drug product
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • June 22, 2013 - NEW COMBINATION
  
  

See also...

• Dulera Consumer Information (Drugs.com)
• Dulera Inhalation Aerosol Consumer Information (Wolters Kluwer)
• Dulera Consumer Information (Cerner Multum)
• Dulera Advanced Consumer Information (Micromedex)
• Mometasone/Formoterol Inhalation Aerosol Consumer Information (Wolters Kluwer)
• Formoterol and mometasone Consumer Information (Cerner Multum)
• Mometasone and formoterol Inhalation Advanced Consumer Information (Micromedex)